About this trial
The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose CT for adults aged 50-80 with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years. Despite insurance coverage, only 17% of eligible Iowans were screened in 2024. Barriers include the complexity of screening and competing demands in primary care. To address these challenges, investigators propose a two-part intervention: a blood-based screening test to simplify LCS and a community pharmacist-led referral program integrated into routine pharmacy care.
Eligible patients will be identified at Greenwood Pharmacy in Waterloo, Iowa. Interested individuals will be consented by a pharmacist and engaged in shared decision-making about LCS. Participants may decline screening, complete the DELFI Diagnostics FirstLook lung cancer screening blood test, or pursue CT screening through their primary care physician. Those choosing the blood test will be referred to Cedar Valley Family Medicine. Patients with a positive result will complete a standard shared decision-making visit with their PCP and, if appropriate, undergo confirmatory CT imaging. Patients with a negative result will enter a screening cohort and be re-screened annually for an additional year.
Eligibility criteria
Qualifiers
aged 50-77
smoking pack-year history of ≥ 20 years
current smoker or quit smoking 15 or less years ago
ability to understand and willingness to sign a written informed consent document
Disqualifiers
self-report of lung cancer screening in the last 12 months
psychiatric illness/social situations that would limit compliance with study requirements
Trial design
Treatments tested in this trial
- DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test
- Low-Does CT Scan